Skip to main content

Advertisement

SpringerLink
Log in

Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients

  • PRECLINICAL STUDIES
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

An Erratum to this article was published on 09 June 2017

Summary

Little is known on factors predicting toxicity of anti-PD1 checkpoint inhibitors. Sarcopenic obesity is associated with increased acute toxicity of cytotoxic agents and targeted therapies. We explored whether body composition also influenced the occurrence of early acute limiting toxicity (ALT) of anti-PD1 in melanoma patients. This is a monocentric, retrospective study analyzing toxicity outcome in consecutive melanoma patients treated with nivolumab or pembrolizumab. Various parameters linked to the patient or the disease status have been analysed. Body mass index (BMI; kg/m2) and muscle mass using CT were measured prior to treatment initiation. Chi-squared test and Mann-Whitney’s tests were used for the comparison of categorical and continuous variables respectively. Among 68 melanoma patients treated with anti-PD1 (47 pembrolizumab, 21 nivolumab), 38 (56%) patients had a BMI ≥ 25 kg/m2 and 11 (16%) a BMI ≥ 30, while 13 (19%) had both sarcopenia and a BMI ≥ 25 kg/m2. For the 11 (16%) patients who experienced early ALT, the mean BMI was higher (27.9 versus 24.7 kg/m2; p = 0.04). Among the 32 female patients, sarcopenic overweight patients had a 6.5-fold increased risk of ALT (50 versus 7.7%; p = 0.01). Sarcopenic overweight is associated with more early ALT of anti-PD1 in melanoma patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ribas A, Puzanov I, Dummer R et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16:908–918. doi:10.1016/S1470-2045(15)00083-2

    Article  CAS  PubMed  Google Scholar 

  2. Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 372:2521–2532. doi:10.1056/NEJMoa1503093

    Article  CAS  PubMed  Google Scholar 

  3. Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330. doi:10.1056/NEJMoa1412082

    Article  CAS  PubMed  Google Scholar 

  4. Weber JS, D’Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375–384. doi:10.1016/S1470-2045(15)70076-8

    Article  CAS  PubMed  Google Scholar 

  5. Huillard O, Mir O, Peyromaure M et al (2013) Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer 108:1034–1041. doi:10.1038/bjc.2013.58

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Prado CMM, Baracos VE, McCargar LJ et al (2007) Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res Off J Am Assoc Cancer Res 13:3264–3268. doi:10.1158/1078-0432.CCR-06-3067

    Article  CAS  Google Scholar 

  7. Michot JM, Bigenwald C, Champiat S et al (1990) (2016) immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer Oxf Engl 54:139–148. doi:10.1016/j.ejca.2015.11.016

    Article  Google Scholar 

  8. Mourtzakis M, Prado CMM, Lieffers JR et al (2008) A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab Physiol Appliquée Nutr Métabolisme 33:997–1006. doi:10.1139/H08-075

    Article  Google Scholar 

  9. Prado CMM, Lieffers JR, McCargar LJ et al (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9:629–635. doi:10.1016/S1470-2045(08)70153-0

    Article  PubMed  Google Scholar 

  10. Barret M, Antoun S, Dalban C et al (2014) Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer 66:583–589. doi:10.1080/01635581.2014.894103

    Article  CAS  PubMed  Google Scholar 

  11. Jung H-W, Kim JW, Kim J-Y et al (2015) Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 23:687–694. doi:10.1007/s00520-014-2418-6

    Google Scholar 

  12. Tan BHL, Brammer K, Randhawa N et al (2015) Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 41:333–338. doi:10.1016/j.ejso.2014.11.040

    CAS  Google Scholar 

  13. Ali R, Baracos VE, Sawyer MB et al (2016) Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. Cancer Med 5:607–616. doi:10.1002/cam4.621

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Sjøblom B, Grønberg BH, Wentzel-Larsen T et al (2016) Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer. Clin Nutr Edinb Scotl. doi:10.1016/j.clnu.2016.03.010

    Google Scholar 

  15. Antoun S, Baracos VE, Birdsell L et al (2010) Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol Off J Eur Soc Med Oncol ESMO 21:1594–1598. doi:10.1093/annonc/mdp605

    Article  CAS  Google Scholar 

  16. Mir O, Coriat R, Blanchet B et al (2012) Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of Sorafenib in patients with hepatocellular carcinoma. PLoS One. doi:10.1371/journal.pone.0037563

    Google Scholar 

  17. Massicotte M-H, Borget I, Broutin S et al (2013) Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study. J Clin Endocrinol Metab 98:2401–2408. doi:10.1210/jc.2013-1115

    Article  CAS  PubMed  Google Scholar 

  18. Martin L, Birdsell L, Macdonald N et al (2013) Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol Off J Am Soc Clin Oncol 31:1539–1547. doi:10.1200/JCO.2012.45.2722

    Article  Google Scholar 

  19. Go S, Park MJ, Song H et al (2016) Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Cachex Sarcopenia Muscle. doi:10.1002/jcsm.12115

    Google Scholar 

  20. Kumar A, Moynagh MR, Multinu F et al (2016) Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer. Gynecol Oncol. doi:10.1016/j.ygyno.2016.05.027

    Google Scholar 

  21. Sabel MS, Lee J, Cai S et al (2011) Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol 18:3579–3585. doi:10.1245/s10434-011-1976-9

    Article  PubMed  Google Scholar 

  22. Wagner D, DeMarco MM, Amini N et al (2016) Role of frailty and sarcopenia in predicting outcomes among patients undergoing gastrointestinal surgery. World J Gastrointest Surg 8:27–40. doi:10.4240/wjgs.v8.i1.27

    Article  PubMed  PubMed Central  Google Scholar 

  23. Downey SG, Klapper JA, Smith FO et al (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res Off J Am Assoc Cancer Res 13:6681–6688. doi:10.1158/1078-0432.CCR-07-0187

    Article  CAS  Google Scholar 

  24. Yousaf N, Davidson M, Goode E et al (2015) The cost of ipilimumab toxicity: a single-centre analysis. Melanoma Res 25:259–264. doi:10.1097/CMR.0000000000000158

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, CERTIM Group, Cochin Port-Royal Hospital, AP-HP, University Paris Descartes, 123 Bd Port-Royal, 75 679, Paris Cedex 14, France

    Valentine Heidelberger, François Goldwasser, Anne Jouinot, Olivier Huillard, Pascaline Boudou-Rouquette, Jennifer Arrondeau & Jérôme Alexandre

  2. Department of Dermatology, CERTIM Group, Cochin Port-Royal Hospital, AP-HP, University Paris Descartes, 123 Bd Port-Royal, 75 679, Paris Cedex 14, France

    Nora Kramkimel, Johan Chanal, Nathalie Franck, Marie-Françoise Avril, Nicolas Dupin & Sélim Aractingi

  3. Department of Pharmacokinetics and Pharmacochemistry, CERTIM Group, Cochin Port-Royal Hospital, AP-HP, University Paris Descartes, 123 Bd Port-Royal, 75 679, Paris Cedex 14, France

    Benoît Blanchet

  4. Department of Biochemistry and Molecular Biology, CERTIM Group, Cochin Port-Royal Hospital, AP-HP, University Paris Descartes, 123 Bd Port-Royal, 75 679, Paris Cedex 14, France

    Karen Leroy

Authors
  1. Valentine Heidelberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. François Goldwasser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nora Kramkimel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anne Jouinot
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Olivier Huillard
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pascaline Boudou-Rouquette
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Johan Chanal
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jennifer Arrondeau
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Nathalie Franck
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jérôme Alexandre
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Benoît Blanchet
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Karen Leroy
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Marie-Françoise Avril
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Nicolas Dupin
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Sélim Aractingi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to François Goldwasser.

Ethics declarations

Conflict of interest

All the authors have no conflict of interest to declare related to the work described in the paper.

Funding

This work has received no funding.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

This article does not contain any studies with animals performed by any of the authors.

Informed consent

For this type of study, formal consent is not required.

Additional information

The original version of this article was revised due to first and last names have been reversed in the list of authors.

An erratum to this article is available at http://dx.doi.org/10.1007/s10637-017-0475-7.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heidelberger, V., Goldwasser, F., Kramkimel, N. et al. Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients. Invest New Drugs 35, 436–441 (2017). https://doi.org/10.1007/s10637-017-0464-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-017-0464-x

Keywords

Search

Navigation